Key Quantitative Figures
Consolidated Financial Results (FY 2025-26):
- Revenue from operations: ₹9,127.84 crore
- Total income: ₹9,178.50 crore
- Net profit for the period: ₹1,064.19 crore
- EBITDA: ₹2,135.64 crore
- Basic EPS from continuing operations: ₹13.80
- Dividend recommended: ₹1 per equity share (10% of face value of ₹10)
Quarterly Performance (Q4 FY26):
- Revenue from operations: ₹2,364.67 crore
- Net profit: ₹271.19 crore
- EBITDA: ₹536.72 crore
- Basic EPS: ₹3.52
Standalone Financial Results (FY 2025-26):
- Revenue from operations: ₹1,957.68 crore
- Net profit: ₹230.34 crore
- EBITDA: ₹562.24 crore
- Basic EPS: ₹3.05
Dates of Action
- Board Meeting Date: May 22, 2026 (commenced at 09:35 IST, concluded at 19:35 IST)
- Financial Year Ended: March 31, 2026
- Dividend payment: Within 30 days from conclusion of AGM, if approved
- Cost Auditor appointment: Effective from May 22, 2026 for FY 2026-27
Parties Involved
- Statutory Auditors: M/s. B S R & Co. LLP (issued unmodified opinion)
- Cost Auditor: M/s Jitender, Navneet & Co. (appointed for FY 2026-27)
- Subsidiaries: 26 subsidiaries included in consolidation
- Joint Ventures: 3 joint ventures included in consolidation
- Associates: 2 associates included in consolidation
Capital Structure Impact
- Paid-up equity share capital: ₹754.96 crore (face value ₹10 per share)
- Dividend payout: Approximately ₹75.50 crore if approved (net cash outflow ~₹75.50 crore)
- ESOP: 1,32,05,200 employee stock options granted post-quarter under "Fortis Healthcare Limited Stock Option Scheme 2026"
Operational Highlights
- Healthcare segment revenue: ₹7,772.69 crore (FY26)
- Diagnostics segment revenue: ₹1,526.56 crore (FY26)
- Segment profit - Healthcare: ₹1,393.70 crore (FY26)
- Segment profit - Diagnostics: ₹241.85 crore (FY26)
Legal and Regulatory Matters
Ongoing Investigations:
- SFIO investigation regarding alleged improper transactions and non-compliances with laws (relating to period prior to March 2018)
- SEBI matters including appeals against penalties imposed on Company and subsidiaries
- Economic Offences Wing (EOW) investigations
- Various court cases including Delhi High Court, Supreme Court matters
Provisioning:
- Company has made provisions for contingencies that may arise from these issues
- Management believes any further additional impact is not expected to be material
Recent Acquisitions/Transactions
- Acquisition of Shrimann Superspecialty Hospital (July 24, 2025) for ₹461.90 crore
- Acquisition of TMI Healthcare Private Limited (January 9, 2026) for ₹433.86 crore
- Sale of Richmond Road Hospital business to Vikram Aura Private Limited (December 12, 2024) for ₹22.75 crore
Corporate Actions
- Composite Scheme of Amalgamation approved by NCLT (effective March 1, 2026)
- Intra-group restructuring scheme approved by NCLT (effective April 1, 2023)
- Brand acquisition: Company acquired "Fortis" brand and allied trademarks through court auction for ₹200 crore
Debt Compliance
- Certificate provided for compliance with covenants for listed non-convertible debt securities
- Net External Debt to EBITDA ratio: 1.08 (consolidated) as of March 31, 2026
- Company complied with all financial and non-financial covenants as per debenture trust deed
Auditor's Emphasis of Matters
Auditors drew attention to:
1. Ongoing SFIO investigation regarding alleged improper transactions (pre-March 2018)
2. Supreme Court order regarding transactions with RHT Health Trust
Opinion not modified in respect of these matters.
Dividend Details
- Recommended final dividend: ₹1 per equity share (10% of face value ₹10)
- Subject to shareholder approval at AGM
- Payment within 30 days from AGM conclusion
- Estimated cash outflow: Approximately ₹75.50 crore
Other Approvals
- Corporate Social Responsibility Policy approved
- Cost Auditor appointment for FY 2026-27
- Publication of financial results in newspapers as per Regulation 47
#Tags: #FortisHealthcare #FY2026Results #SEBIDisclosure #Dividend #Healthcare #RegulatoryCompliance #FinancialResults